Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19815033 | 0.96 | CRBN (0.31) | CRBNDDB1 | |
| SCHEMBL19815023 | 0.95 | KMT2A (0.33) | CRBNDDB1 | |
| SCHEMBL2159192 | 0.92 | CRBN (0.33) | CRBNDDB1 | |
| SCHEMBL19817308 | 0.84 | ALDH1A1 (0.34) | — | |
| SCHEMBL17112824 | 0.79 | DDB1 (0.30) | CRBNDDB1 | |
| SCHEMBL17611698 | 0.78 | CRBN (0.40) | CRBNDDB1 | |
| SCHEMBL21197226 | 0.76 | USP30 (0.44) | CRBNDDB1 | |
| SCHEMBL5895840 | 0.76 | SPR (0.35) | CRBNDDB1 | |
| SCHEMBL18321890 | 0.74 | SPR (0.36) | CRBNDDB1 | |
| SCHEMBL505075 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3490982-B1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LTD (GB) | 2022-04-20 | — | — | EP | disclosed |
| US-20220002264-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2022-01-06 | — | — | US | disclosed |
| US-11053213-B2 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| US-20190233394-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2019-08-01 | — | — | US | disclosed |
| EP-3490982-A1 | PHARMACEUTICAL COMPOUNDS | Almac Discovery Limited (GB) | 2019-06-05 | — | — | EP | disclosed |
| WO-2018020242-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2018-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233394-A1 | PHARMACEUTICAL COMPOUNDS | USP19, USP18, UBE2I | CRBN 422/4885DDB1 2736/4885 |
| US-20220002264-A1 | PHARMACEUTICAL COMPOUNDS | USP19, USP18, UBE2I | CRBN 422/4885DDB1 2736/4885 |
| US-11053213-B2 | Pharmaceutical compounds | USP19, USP18, UBE2I | CRBN 422/4885DDB1 2736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.